Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Income towards Parent Company for 7 consecutive years, with -$5.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income towards Parent Company fell 10.17% year-over-year to -$5.5 million in Q2 2026; TTM through Jun 2026 was -$25.6 million, a 78.24% decrease from a year earlier, with the FY2025 full-year figure at -$21.2 million, down 89.66% from the prior year.
• Income towards Parent Company was -$5.5 million for Q2 2026 at Vivos Therapeutics, up from -$7.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$1.7 million in Q1 2023 and troughed at -$7.8 million in Q1 2026.
• A 5-year average of -$4.6 million and a median of -$5.2 million in 2022 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company surged 68.05% in 2023 and tumbled 159.74% in 2025, its largest moves.
• Over 5 years, Income towards Parent Company stood at -$6.2 million in 2022, then surged by 30.49% to -$4.3 million in 2023, then soared by 32.94% to -$2.9 million in 2024, then slumped by 141.04% to -$7.0 million in 2025, then advanced by 20.58% to -$5.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$5.5 million (Q2 2026), -$7.8 million (Q1 2026), and -$7.0 million (Q4 2025), per Business Quant data.